Ptc Therapeutics Inc Quick Ratio (PTCT) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Ptc Therapeutics inc   (NASDAQ: PTCT)

Ptc Therapeutics Inc 's Quick Ratio

PTCT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 2.74 below Ptc Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 238 other companies have achieved higher Quick Ratio than Ptc Therapeutics Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 0 to 1137.

Explain Quick Ratio?
How much Cash & cash equivalents PTCT´s has?
What are PTCT´s Current Liabilities?




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/PTCT/financial-strength
https://api.csimarket.com/api/v1/companies/PTCT/fundamentals
https://api.csimarket.com/api/v1/companies/PTCT/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
PTCT Quick Ratio (Sep 30 2026)
Q3
(Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
Y / Y Current Liabilities Change -10.41 %
Y / Y Cash & cash equivalent Change 26.08 %
Quick Ratio MRQ 2.74
PTCT's Total Ranking # 1137
Seq. Current Liabilities Change 0.65 %
Seq. Cash & cash equivalent Change -4.54 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 239
Healthcare Sector # 410
Overall Market # 1137


Quick Ratio Statistics
High Average Low
26.69 4.67 0.09
(Mar 31 2014)   (Dec 31 2012)




Financial Statements
Ptc Therapeutics Inc 's Current Liabilities $ 776 Millions Visit PTCT's Balance sheet
Ptc Therapeutics Inc 's Cash & cash equivalent $ 2,128 Millions Visit PTCT's Balance sheet
Source of PTCT's Sales Visit PTCT's Sales by Geography


Cumulative Ptc Therapeutics Inc 's Quick Ratio

PTCT's Quick Ratio for the trailling 12 Months

PTCT Quick Ratio

(Sep 30 2026)
12 Months
(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 28.96 %
Y / Y Cash & cash equivalent TTM Growth 30.14 %
Quick Ratio TTM 2.38
Total Ranking TTM # 3953
Seq. Current Liabilities TTM Growth -2.55 %
Seq. Cash & cash equivalent TTM Growth 5.68 %


On the trailing twelve months basis PTCT Cash & cash equivalent grew by 26.08 % in Q3 2026 year on year, while Current Liabilities rose to $776 millions, this led to increase in in Ptc Therapeutics Inc 's Quick Ratio to 2.38, above PTCT average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 435 other companies have achieved higher Quick Ratio than Ptc Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 0 to 3953.

Explain Quick Ratio?
How much Cash & cash equivalents PTCT´s has?
What are PTCT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 436
Healthcare Sector # 893
Within the Market # 3953


trailing twelve months Quick Ratio Statistics
High Average Low
11.84 1.66 0.3
(Jun 30 2019)   (Sep 30 2022)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Braveheart Bio, Inc.  7.27 $ 121.291  Millions$ 16.673  Millions
Viking Therapeutics Inc   7.17 $ 959.813  Millions$ 133.897  Millions
Scynexis Inc   7.09 $ 47.165  Millions$ 6.652  Millions
Lb Pharmaceuticals Inc  7.03 $ 215.075  Millions$ 30.573  Millions
Zentalis Pharmaceuticals Inc   7.03 $ 228.893  Millions$ 32.539  Millions
Quoin Pharmaceuticals Ltd   6.95 $ 33.184  Millions$ 4.776  Millions
Vera Therapeutics Inc   6.89 $ 384.042  Millions$ 55.775  Millions
Nuvation Bio Inc   6.73 $ 663.370  Millions$ 98.559  Millions
Coya Therapeutics Inc   6.64 $ 35.802  Millions$ 5.395  Millions
Capricor Therapeutics inc   6.61 $ 197.581  Millions$ 29.895  Millions
Arcturus Therapeutics Holdings Inc   6.52 $ 184.817  Millions$ 28.345  Millions
Moonlake Immunotherapeutics  6.50 $ 379.704  Millions$ 58.430  Millions
Camp4 Therapeutics Corporation  6.27 $ 124.522  Millions$ 19.865  Millions
Context Therapeutics Inc   6.26 $ 34.411  Millions$ 5.501  Millions
Bridgebio Oncology Therapeutics Inc   6.18 $ 315.331  Millions$ 51.026  Millions
Cartesian Therapeutics Inc   6.12 $ 122.975  Millions$ 20.088  Millions
Olema Pharmaceuticals Inc   5.98 $ 413.771  Millions$ 69.233  Millions
Summit Therapeutics Inc   5.71 $ 629.899  Millions$ 110.226  Millions
Nurix Therapeutics Inc   5.51 $ 720.458  Millions$ 130.742  Millions
United Therapeutics Corporation  5.51 $ 3,439.800  Millions$ 624.300  Millions
Immuneering Corporation  5.45 $ 58.776  Millions$ 10.791  Millions
Aquestive Therapeutics Inc   5.22 $ 90.349  Millions$ 17.299  Millions
Sionna Therapeutics Inc   5.11 $ 83.878  Millions$ 16.420  Millions
Gain Therapeutics inc  4.94 $ 11.698  Millions$ 2.369  Millions
Rani Therapeutics Holdings Inc   4.91 $ 45.288  Millions$ 9.223  Millions
Abeona Therapeutics Inc   4.87 $ 134.941  Millions$ 27.707  Millions
Shattuck Labs Inc   4.84 $ 61.758  Millions$ 12.758  Millions
Mereo Biopharma Group Plc  4.75 $ 26.097  Millions$ 5.494  Millions
Spruce Biosciences Inc   4.69 $ 87.691  Millions$ 18.710  Millions
Septerna Inc   4.56 $ 478.601  Millions$ 104.863  Millions

Date modified: 2026-10-30T13:21:26+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.